ACHN - Achillion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1900
-0.1100 (-4.78%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.3000
Open2.3000
Bid2.18 x 28000
Ask2.42 x 1100
Day's Range2.1700 - 2.3282
52 Week Range1.2900 - 4.3400
Volume2,153,825
Avg. Volume2,548,737
Market Cap303.569M
Beta (3Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateFeb 20, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
    Motley Fool11 days ago

    Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December

    A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.

  • MoneyShow11 days ago

    Top Picks 2019- Achillian Pharmaceuticals ACHN

    The biotechnology sector really got hammered in 2018. In December the markets took many quality small cap biotechs down to historic low prices, observes Bill Mathews, small cap expert and editor of The Cheap Investor.

  • Benzinga18 days ago

    The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

    Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.

  • GlobeNewswire18 days ago

    Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by disorders of the complement system, today announced that the Company’s Board of Directors has elected Nicole Vitullo Chair. Ms. Vitullo is a partner with Domain Associates LLC and has been a member of Achillion's Board of Directors since September 2010.

  • ACCESSWIRE21 days ago

    4 Healthcare Stocks That Are Raising Eyebrows

    CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.

  • Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day
    Motley Foollast month

    Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day

    The aftermath from its disappointing pipeline update early in the week continued to hurt the biotech stock.

  • Why Achillion Pharmaceuticals Sank Again Today
    Motley Foollast month

    Why Achillion Pharmaceuticals Sank Again Today

    Reverberations from the biotech's pipeline update on Monday continued to weigh on the stock.

  • Achillion Reports Positive Interim Data on Factor D Inhibitors
    Zackslast month

    Achillion Reports Positive Interim Data on Factor D Inhibitors

    Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.

  • Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today
    Motley Foollast month

    Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today

    Some stocks missed out on the day's minor rally.

  • Benzingalast month

    The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Shares of Achillion Pharmaceuticals were in the red on Monday as traders waited for interim clinical-trial data from the company. Synergy Pharmaceuticals saw its shares explode on news from Cipher Pharmaceuticals Inc. announcing that its New Drug Submission for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide from Synergy earlier this year.

  • Why Achillion Pharmaceuticals Crashed Today
    Motley Foollast month

    Why Achillion Pharmaceuticals Crashed Today

    Worries about an imminent clinical update sent the stock lower.

  • GlobeNewswirelast month

    Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated disorders, today reported interim results for the Company’s Phase 2 trials of its first-generation oral factor D inhibitor, ACH-4471, as well as Phase 1 pharmacokinetics and potency data for its next-generation factor D inhibitors, ACH-5228 and ACH-5548. “These compelling findings underscore the momentum for Achillion and our factor D portfolio as we advance three oral small molecule compounds through clinical development.

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    Biotech stocks staged a modest comeback this week ending along with the broader market. The week saw a spate of clinical trial results releases , sending stocks moving in either direction. The tally of ...

  • Should You Buy Achillion Pharmaceuticals, Inc. (ACHN)?
    Insider Monkeylast month

    Should You Buy Achillion Pharmaceuticals, Inc. (ACHN)?

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]

  • GlobeNewswirelast month

    Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018

    Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced today that the company will host a live webcast and conference call on December 17th at 4:30PM EST. Joseph Truitt, President and Chief Executive Officer and Dr. Stephen Zelenkofske, Executive Vice President and Chief Medical Officer will present Achillion’s 2019 development plans along with interim data for the Company’s Phase 2 clinical trials in PNH and C3G as well as initial Phase 1 data on Achillion’s next generation factor D inhibitors.

  • RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy?
    Insider Monkeylast month

    RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy?

    The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]

  • Implied Volatility Surging for Achillion (ACHN) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Achillion (ACHN) Stock Options

    Achillion (ACHN) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Associated Press2 months ago

    Achillion: 3Q Earnings Snapshot

    On a per-share basis, the New Haven, Connecticut-based company said it had a loss of 12 cents. The company's shares closed at $2.95. A year ago, they were trading at $4. _____ This story was generated ...

  • Simply Wall St.3 months ago

    Does Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Have A Volatile Share Price?

    If you’re interested in Achillion Pharmaceuticals Inc (NASDAQ:ACHN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

    The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

  • IPOs and Foreign Investment Propel Biotech: 4 Top Picks
    Zacks4 months ago

    IPOs and Foreign Investment Propel Biotech: 4 Top Picks

    A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.